Emerging Car T Therapies in Hematologic Malignancies: Jae H. Park, MD
The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.
Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies
Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.
Dr. Park on Updates With CAR T Cells in ALL
Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.
Dr. Park Discusses Use of CAR T Cells in ALL
Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T cells in the treatment of patients with acute lymphoblastic leukemia.
Dr. Park on Challenges With CAR T-Cell Therapies in AML
Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.
2 Clarke Drive Cranbury, NJ 08512